Smart move. Partnering is hard. By extending the Acadia partnership, which appears to be going well, Neuren has avoided having to deal with other companies (other languages, other time zones) in other parts of the world. Acadia will have the responsibility now to set up overseas offices, not Neuren, who can concentrate on their core business which is developing and getting new drugs to market.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-33
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.40 |
Change
1.130(8.52%) |
Mkt cap ! $1.840B | |||
| Open | High | Low | Value | Volume |
| $13.80 | $14.45 | $13.53 | $15.04M | 1.062M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 871 | $14.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.42 | 3650 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |